GlassScriptPhysician profile
Myint Zaw
NPI 1063527463
$8,685.86
in general payments reported to CMS, 2019-2025
34 companies · $797 in 2025
The $797 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,551 · 2020: $1,022 · 2021: $1,142 · 2022: $1,099 · 2023: $1,219 · 2024: $857 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.81 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,359.98 | 2019-2025 | Breztri, Airsupra, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $1,274.73 | 2019-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $704.77 | 2019-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $676.65 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $636.17 | 2019-2025 | Ozempic |
| Pfizer INC. | $520.13 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.15 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $216.24 | 2019-2024 | Rexulti |
| Abbvie INC. | $205.20 | 2021-2024 | Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.30 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $174.21 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $159.04 | 2019 | |
| Averitas Pharma INC. | $125.00 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $122.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $121.24 | 2021 | |
| Daiichi Sankyo INC. | $110.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $98.89 | 2019 | |
| Edwards Lifesciences Corporation | $81.34 | 2019 | |
| Amgen INC. | $69.87 | 2019 | |
| Merck Sharp & Dohme LLC | $50.51 | 2019-2020 | |
| Forte Bio-Pharma LLC | $45.92 | 2024 | Prolate, Nalocet |
| Vertex Pharmaceuticals Incorporated | $41.33 | 2024-2025 | |
| Horizon Therapeutics Plc | $40.60 | 2021 | |
| Mannkind Corporation | $24.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2019 | |
| Exact Sciences Corporation | $22.00 | 2023 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $21.00 | 2019 | |
| Medtronic, INC. | $17.72 | 2024 | Intellis Adaptivestim |
| Eisai INC. | $17.64 | 2020 | |
| Seqirus USA INC | $16.92 | 2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2019 | |
| Allergan, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myint Zaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.